about
Identification and characterization of ovarian cancer-initiating cells from primary human tumorsSmall molecule inhibitors target the tissue transglutaminase and fibronectin interactionCarboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Studyβ-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroidsA phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.Tissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism.Decitabine reactivated pathways in platinum resistant ovarian cancer.A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancerEpigenetic targeting of ovarian cancer stem cellsOlaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients.In vivo tumor growth of high-grade serous ovarian cancer cell linesAn open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancerTissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer ProgressionTissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.Complete Transcriptome RNA-Seq.TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells.Intracellular Doppler Signatures of Platinum Sensitivity Captured by Biodynamic Profiling in Ovarian Xenografts.Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancerNovel agents in ovarian cancer.Epigenetic resensitization to platinum in ovarian cancerContinued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysisNF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study.Minireview: epigenetic changes in ovarian cancer.Epithelial ovarian cancer experimental models.EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.Adjuvant therapy for endometrial cancer.Targeting angiogenesis in ovarian cancer.Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study.Endoglin for targeted cancer treatment.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
P50
Q24644329-84F05C86-E84E-4A17-BE5C-312C5C5DEC8EQ28540004-C8981F2F-A50E-41C3-AA26-E6CD0E048A54Q28550381-D8C876F8-649E-400D-B9AC-2DC466C21A55Q30370274-5E2DE620-AD23-44C7-8F47-FFC007FD8578Q33380697-2C55C20D-C546-4A43-AE63-4A5AA87551C9Q33397386-BD5CF2C4-EC18-48CF-B49D-C76968DC21A7Q33621141-39FA8DEF-7F07-4FE3-943D-573A455C3FC0Q33730021-8BA45423-F340-4A0A-8E83-75F8782E3DBAQ33976957-B198A59F-8414-4EB8-AA02-82E4B82F005BQ34091420-87BC95E3-B95E-4443-9C1B-D74758877FFFQ34135466-5D0E47E8-3E08-4C0E-BA43-089839ED2A82Q34422265-7F973A99-1097-4268-B667-A45D9495F5BAQ34717933-623E9471-B3FC-4E2D-8C72-C06C81703A32Q35684905-84E93ADF-7B67-4944-B97B-4C06D4975E4AQ35874750-06BB24A7-0055-4DD9-B130-3408C617301CQ35927115-0FE6F39E-B2F0-408F-AADF-7912DF9A1184Q36061812-111C22C8-703B-46AA-9C5E-14EAA3799BD8Q36067023-47AB6E66-3504-414E-8965-099B2EB48800Q36117713-7059D9C8-9BF0-4350-86F3-3D386A603E28Q36177354-F7F4E150-57EE-4243-B8E1-D1B59845FA4DQ36180848-D7D035EB-F2C6-4690-8931-10B00240CB0EQ36213724-D47B0F9B-EBB3-4433-AAD7-13C4506A545AQ36237226-F95B255A-F2B2-4764-B6CE-648BE97DB46FQ36432553-4ECDB23A-EBC1-48C9-B4E4-AF258359FC11Q36746785-9C8A184F-5F5F-4FF6-9B53-E169B04D80B3Q36879220-536EB3E7-8425-43A3-8FEA-30D5BC17A67DQ36904860-2A5F3B3B-78FB-4701-B34D-F0C65349DC59Q36979382-096857C9-83C6-466A-8ED1-BFA21017135AQ37086928-89F7D611-2E13-4ADB-8EE0-CB267ECBEC62Q37309839-CB595421-46FE-47D5-ABE2-A56D0CEB1E45Q37325094-CBA38F72-4058-47C4-8422-EEDF417ADE8FQ37328836-F6244916-E737-48F6-914E-31529939F4DFQ37708938-2F9268BA-A731-4773-BE22-9B2AD6FF1D3EQ37708968-0379754E-1F62-4BCD-B35D-FA5987DF2C08Q37717743-565883CC-5DF6-4B6A-BA87-20C7B63AA62BQ37901942-7C6A55BA-A3BF-4342-943E-957B358CE001Q38152755-825BCB76-F145-4075-B39E-7E29E57BCC69Q38180309-E414B4DC-586C-45D8-B8DF-6E1BBD4996EDQ38387666-5B336E45-50A3-4432-90CE-994B43A5FBF2Q38393818-F69B44DB-DAA2-4F01-9FD9-A0050EEC88E1
P50
description
investigador
@es
researcher
@en
name
Daniela Matei
@en
Daniela Matei
@nl
type
label
Daniela Matei
@en
Daniela Matei
@nl
prefLabel
Daniela Matei
@en
Daniela Matei
@nl
P31
P496
0000-0003-2169-5035